Patents by Inventor Lewis Cantley

Lewis Cantley has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Targeting the glutamine to pyruvate pathway for treatment of oncogenic Kras-associated cancer
    Patent number: 10837015
    Abstract: Methods and kits for GPP-targeting, e.g., for the treatment of oncogenic Kras-associated cancers, and methods for determining the efficacy of those methods are provided.
    Type: Grant
    Filed: October 12, 2018
    Date of Patent: November 17, 2020
    Assignees: Dana-Farber Cancer Institute, Inc., Beth Israel Deaconess Medical Center, Inc.
    Inventors: Alec C. Kimmelman, Jaekyoung Son, Lewis Cantley, Costas A. Lyssiotis
  • TARGETING THE GLUTAMINE TO PYRUVATE PATHWAY FOR TREATMENT OF ONCOGENIC KRAS-ASSOCIATED CANCER
    Publication number: 20190136238
    Abstract: Methods and kits for GPP-targeting, e.g., for the treatment of oncogenic Kras-associated cancers, and methods for determining the efficacy of those methods are provided.
    Type: Application
    Filed: October 12, 2018
    Publication date: May 9, 2019
    Inventors: Alec C. Kimmelman, Jaekyoung Son, Lewis Cantley, Costas A. Lyssiotis
  • Targeting the glutamine to pyruvate pathway for treatment of oncogenic Kras-associated cancer
    Patent number: 10138479
    Abstract: Methods and kits for GPP-targeting, e.g., for the treatment of oncogenic Kras-associated cancers, and methods for determining the efficacy of those methods are provided.
    Type: Grant
    Filed: May 23, 2013
    Date of Patent: November 27, 2018
    Assignees: Dana-Farber Cancer Institute, Inc., Beth Israel Deaconess Medical Center, Inc.
    Inventors: Alec Kimmelman, Jaekyoung Son, Lewis Cantley, Costas A. Lyssiotis
  • Methods for diagnosing and treating oncogenic kras-associated cancer
    Patent number: 9745631
    Abstract: Methods for diagnosing and treating cancer associated with an oncogenic Kras mutation in a subject are provided.
    Type: Grant
    Filed: December 19, 2012
    Date of Patent: August 29, 2017
    Assignees: Dana-Farber Cancer Institute, Inc., Beth Israel Deaconess Medical Center, Inc.
    Inventors: Ronald A. DePinho, Lewis Cantley, Alec C. Kimmelman, Haoqiang Ying, Costas A. Lyssiotis
  • METHODS FOR DIAGNOSING AND TREATING ONCOGENIC KRAS-ASSOCIATED CANCER
    Publication number: 20150126580
    Abstract: Methods for diagnosing and treating cancer associated with an oncogenic Kras mutation in a subject are provided.
    Type: Application
    Filed: December 19, 2012
    Publication date: May 7, 2015
    Inventors: Ronald A. DePinho, Lewis Cantley, Alec C. Kimmelman, Haoqiang Ying, Costas A. Lyssiotis
  • TARGETING THE GLUTAMINE TO PYRUVATE PATHWAY FOR TREATMENT OF ONCOGENIC KRAS-ASSOCIATED CANCER
    Publication number: 20150110773
    Abstract: Methods and kits for GPP-targeting, e.g., for the treatment of oncogenic Kras-associated cancers, and methods for determining the efficacy of those methods are provided.
    Type: Application
    Filed: May 23, 2013
    Publication date: April 23, 2015
    Inventors: Alec C. Kimmelman, Jaekyoung Son, Lewis Cantley, Costas A. Lyssiotis
  • Inhibitors of pyruvate kinase and methods of treating disease
    Patent number: 8877791
    Abstract: The invention provides pharmaceutical compositions, kits, and methods of treating cancer, diabetes, obesity, autoimmune disease, and benign prostatic hyperplasia using compounds that selectively inhibit pyruvate kinase M2 and an assay measuring chemical modulation of pyruvate kinase activity.
    Type: Grant
    Filed: August 6, 2007
    Date of Patent: November 4, 2014
    Assignee: Beth Israel Deaconess Medical Center, Inc.
    Inventors: Lewis Cantley, Matthew G. Vander Heiden, Heather R. Christofk
  • INHIBITORS OF PYRUVATE KINASE AND METHODS OF TREATING DISEASE
    Publication number: 20100099726
    Abstract: The invention provides pharmaceutical compositions, kits, and methods of treating cancer, diabetes, obesity, autoimmune disease, and benign prostatic hyperplasia using compounds that selectively inhibit pyruvate kinase M2 and an assay measuring chemical modulation of pyruvate kinase activity.
    Type: Application
    Filed: August 6, 2007
    Publication date: April 22, 2010
    Inventors: Lewis Cantley, Matthew Vander Heiden, Heather R. Christofk
  • Wortmannin conjugates and uses thereof
    Publication number: 20090324489
    Abstract: The invention features conjugates of wortmannin, and wortmannin derivatives, and their use as inhibitors of PI3-kinase activity in treating cancer, inflammatory diseases, and C. albicans infections.
    Type: Application
    Filed: August 31, 2006
    Publication date: December 31, 2009
    Inventors: Hushan Yuan, Ji Luo, Ralph Weissleder, Lewis Cantley, Lee Josephson
  • Modulation of type IIß phosphoinositide phosphate kinase
    Publication number: 20060089320
    Abstract: The invention provides methods for modulating type II? phosphoinisitide phosphate kinase (PIPKII?) activity for treating PIPKII?-associated disorders. The invention also provides methods of identifying candidate agents for treating PIPKII?-associated disorders.
    Type: Application
    Filed: February 3, 2003
    Publication date: April 27, 2006
    Inventors: Lewis Cantley, Katja Lamia, Lucia Rameh, Barbara Kahn, Odile Peroni
  • Products and processes for modulating peptide-peptide binding domain interactions
    Publication number: 20050196808
    Abstract: The present invention relates to therapeutic compounds and methods of use of these therapeutic compounds for treating cellular proliferative disorders. The invention also provides three-dimensional structures of a Polo-like kinase and methods for designing or selecting small molecule inhibitors using these structures, and the therapeutic use of such compounds. The invention also includes a method for identifying novel phosphopeptide-binding domains.
    Type: Application
    Filed: November 14, 2003
    Publication date: September 8, 2005
    Inventors: Michael Yaffe, Andrew Elia, Peter Rellos, Lewis Cantley, Stephen Smerdon, Isaac Manke
  • Modulators of p85 expression
    Publication number: 20040028683
    Abstract: Methods of treating a subject having an insulin-related disorder, e.g., diabetes. The methods include reducing the amount of p85 PI3K regulatory subunit isoform in a cell of the subject.
    Type: Application
    Filed: June 2, 2003
    Publication date: February 12, 2004
    Applicants: Joslin Diabetes Center, Inc., a Massachusetts corporation, Beth Israel Deaconess Medical Center, Inc., a Massachusetts corporation
    Inventors: C. Ronald Kahn, Kohjirro Ueki, Frank Mauvais-Jarvis, David Fruman, Lewis Cantley
  • Inhibitors of phosphoserine and phosphothreonine-proline-specific isomerases
    Publication number: 20030109423
    Abstract: Inhibitors of phosphoserine- or phosphothreonine-specific pepidyl prolyl isomerases are described.
    Type: Application
    Filed: July 10, 2002
    Publication date: June 12, 2003
    Applicant: Max-Planck-Gesellschaft zur Forderung der and Beth Israel Deaconess Medical Center
    Inventors: Kun Ping Lu, Lewis Cantley, Michael Yaffe, Gunter Fischer
  • Inhibitors of phosphoserine and phosphothreonine-proline-specific isomerases
    Patent number: 6462173
    Abstract: Inhibitors of phosphoserine- or posphothreonine-specific peptidyl prolyl isomerases are described. Such inhibitors include molecules that mimic the structure and conformation of the pSer/pThr-Pro peptide moiety of the isomerase substrate when the substrate is bound into the active site of the isomerase. For example, a protein, peptide or peptide mimetic including xSer/ThrY where x is a negatively charged tetra or pentavalent moiety and Y is a Pro or a Pro analog. Methods of inhibiting cell growth and methods of identifying phosphoserine- or phosphothreonine-proline specific peptidyl-prolyl isomerase inhibitors are also included in the invention.
    Type: Grant
    Filed: December 11, 1997
    Date of Patent: October 8, 2002
    Assignees: Max-Planck-Gesellschaft zur Forderung der, Beth Israel Deaconess Medical Center
    Inventors: Kun Ping Lu, Lewis Cantley, Michael Yaffe, Gunter Fischer
  • Modulators of p85 expression
    Publication number: 20020051786
    Abstract: Methods of treating a subject having an insulin-related disorder, e.g., diabetes. The methods include reducing the amount of p85 P13K regulatory subunit isoform in a cell of the subject.
    Type: Application
    Filed: June 22, 2001
    Publication date: May 2, 2002
    Inventors: C. Ronald Kahn, Kohjirro Ueki, Frank Mauvais-Jarvis, David Fruman, Lewis Cantley